作者：周源/华尔街见闻 8月21日，科大讯飞发布2025年上半年财报。 报告期内，科大讯飞营收首次突破百亿元大关，达109.11亿元，同比增幅超17%；归母净利润虽仍亏损 （-2.39亿元），但较2024年同期的亏损额4亿元大幅收窄；销售回款亦首破百亿，经营现金流改善显 著；研发与市场投入持续保持高强度，教育、医疗与C端消费者业务成为当期亮点。 就整体来看，科大讯飞正在迈入从"规模扩张"到"价值兑现"的关键阶段。截至8月21日A股收盘，科大讯 飞当天上涨2.43%，报收52.22元。 销售回款首破百亿大关 半年报显示，2025年上半年，科大讯飞实现营收109.11亿元，首次跨越百亿关口，同比增长17.01%；毛 利43.89亿元，同比提升17.12%；归母净利润为-2.39亿元，2024年同期为-4亿元，相当于同比减亏 40.37%，扣非净利润-3.64亿元，2024年同期为-4.83亿元，即同比减亏24.62%。 这表明，科大讯飞在报告期内不仅扩大了收入规模，同时毛利率质量也保持了稳定，并没有因为快速扩 张而出现毛利率明显下滑的情况。 尽管当期科大讯飞尚未实现盈利，但亏损收窄的幅度值得关注，净利润和扣非净利 ...

8月21日晚间，科大讯飞发布2025年上半年财报。财报显示，科大讯飞上半年营收首次突破百亿，达109.11 亿元，同比增长17.01%。上半年销售回款首次突破百亿，达103.61亿元，同比多增13.50亿元。归母净利 润-2.39亿元，同比减亏40.37%，经营活动现金流量净额增长超过7.64亿元，同比提升49.73%，公司经营保 持良好健康度。 科大讯飞表示，AI出海方面的探索带来新增量，有望成为科大讯飞增长的新引擎。据财报显示，科大讯飞 海外AI硬件同比增长超3倍，AI办公本在日本上市两个月即成为日本最大Makuake众筹平台销售额有史以来 平板类Top1，韩国Wadiz平台2025年全品类TOP1。不仅如此，依托在教育、医疗等垂直行业的技术积累， 科大讯飞伴随国家共建"一带一路"倡议在国产大模型出海上正获得新的增量空间。在2025世界数字教育大 会上，科大讯飞向全球80多个国家和地区的代表展示了中国在人工智能+教育方向的应用成果，吸引了多 国教育部长的高度关注。 基于自主可控的底座大模型，科大讯飞在教育、医疗等核心领域已进行人工智能深度场景落地，形成行业 先发优势和企业发展"护城河"。 当前，人工智能产 ...

8月21日晚间，科大讯飞发布2025年上半年财报。财报显示，科大讯飞上半年营收首次突破百亿，达 109.11亿元，同比增长17.01%，毛利43.89亿元，较上年同期增长17.12%。其中，AI医疗业务上半年收 入同比增长21%。 截至6月30日，讯飞智医助理已拓展至697个区县超7.5万个基层医疗机构，累计提供10.1亿余次AI辅诊 建议，累计识别不合理处方1.1亿分；个人医疗AI助手讯飞晓医APP累计完成超1.4亿次AI咨询量，用户 好评率达98%，用户主动推荐率达46%；慢病管理系统加速全国规模化部署，已覆盖10余个省市120余 个重点区县。（智通财经） ...

商业化落地成效显著，四大业务板块协同发展。基层解决方案持续领跑，智医助理覆盖全国31个省市的 697个区县、超7.5万家基层医疗机构，累计提供超10.1亿次AI辅诊建议，修正诊断超176万例。医院解 决方案合作等级医院超500家；个人健康服务方面，讯飞晓医APP累计提供超1.4亿次咨询服务，下载量 突破2400万次，智能助听器线上线下全渠道布局进一步完善。 医疗AI领军企业讯飞医疗(2506.HK)发布2025年中期业绩。报告期内，公司的基层解决方案、区域解决 方案收入分别同比增长52%、178%，患者管理服务收入同比增长10%，整体营收达2.986亿元，同比增 长30%。 ...

Core Insights - Global ESG investment is increasingly integrated into mainstream investment decisions, with domestic ESG fund issuance remaining robust, totaling 240 new products and 1716.83 billion units in the past year [1] - As of July 20, the total number of existing ESG funds reached 906, with a net asset value of 10297.98 billion yuan, indicating a strong growth trend in ESG considerations for sustainable corporate development [1] - Companies with superior ESG performance are recognized for their advantages in risk management, innovation, and long-term resilience, leading to more stable and sustainable returns [1] Group 1: ESG Ratings and Company Performance - iFlytek Medical was recently rated A in the Wind ESG rating, achieving a comprehensive score of 7.55, which surpasses the industry average of 6.08 [1][4] - The company scored particularly well in governance, with an information security score of 8.04, significantly higher than the industry average of 3.91 [2] - iFlytek Medical's business model, which includes a comprehensive AI healthcare solution, demonstrates a low-carbon attribute with energy consumption of only 0.17 tons of standard coal per million yuan of revenue [3] Group 2: Social Impact and Technological Innovation - The company has addressed social challenges by deploying its AI assistant across 31 provinces, serving over 230,000 grassroots doctors and providing over 10 billion AI-assisted diagnostic suggestions [3] - iFlytek Medical's unique business model, which encompasses various healthcare services, allows it to respond effectively to the demand for equitable healthcare [3] - The company has made significant technological advancements, launching the iFlytek Spark X1 model, which outperforms international AI models in medical tasks, marking a major leap in capabilities [5][6] Group 3: Long-term Growth and Strategic Vision - iFlytek Medical's ESG practices are rooted in its commitment to technology innovation and sustainable development, aiming to redefine the standards of ESG in the medical technology sector [7] - The company is expanding its international presence with the launch of the Spark Medical Model V2.5 International Edition and the upgraded iFlytek Xiaoyi APP, marking a significant step in its global strategy [6] - The recent A rating from Wind ESG not only certifies the company's compliance but also supports its core strategy of using AI to address real medical challenges [4][8]

Group 1 - The core viewpoint of the article highlights the rapid scaling of AI applications in the healthcare sector, driven by government policies and the urgent need for technological integration in the industry [1] - The global digital healthcare market is experiencing a strong rebound in investment, with a 47% quarter-on-quarter increase in funding to reach $5.3 billion in Q1 2023, marking the highest quarterly peak since Q2 2022, despite a 9% decrease in the number of transactions [2][4] - China's digital healthcare market is particularly noteworthy, with Q1 2023 investment amounting to 5 billion yuan, reflecting a remarkable 150% increase compared to the previous quarter [2] Group 2 - iFlytek Healthcare has launched the "Spark Medical Model V2.5 International Version" and upgraded its AI health assistant app, marking a significant leap in its core capabilities and global strategy [5][6] - The new model features six core capabilities, including vast medical knowledge Q&A and complex language understanding, with a revolutionary "fast-slow thinking" mechanism that enhances decision-making in complex medical scenarios [6][7] - The iFlytek Xiaoyi app now covers over 1,600 diseases and 50,000 drugs, achieving a 97% medical OCR recognition rate and 98% coverage of mainstream domestic test reports, significantly improving diagnostic accuracy and report readability [7][8] Group 3 - iFlytek Healthcare's expansion into Hong Kong serves as a strategic launchpad for global market penetration, leveraging its bilingual capabilities and unique market position as the first "medical model stock" listed on the Hong Kong Stock Exchange [10][11] - The company has established a robust market presence, covering over 69,200 grassroots institutions and completing over 1 billion AI-assisted diagnoses, reinforcing its technological leadership [11][12] - iFlytek Healthcare's diversified business model has shown significant growth, with G-end revenue increasing by 10% to 391 million yuan, B-end revenue surging by 103.4% to 132 million yuan, and C-end revenue growing by 56.6% to 211 million yuan [12][13] Group 4 - The global AI healthcare market is projected to grow from $13.7 billion in 2022 to $155.3 billion by 2030, at a compound annual growth rate of 35.5%, indicating substantial growth potential for iFlytek Healthcare [14][15] - The company's strategic initiatives and technological advancements are expected to enhance its market valuation, as evidenced by the 50% increase in the Hang Seng Healthcare Index since the beginning of the year [17][18] - Institutional recognition of iFlytek Healthcare's unique value proposition has increased, with several firms issuing buy or hold ratings based on its clear commercialization prospects and validated growth momentum [18]

Core Viewpoint - iFlytek Medical has officially launched the international version of the Spark Medical Model V2.5, enhancing its iFlytek Xiaoyi APP and introducing a Hong Kong version [1] Group 1 - The Spark Medical Model V2.5 international version supports multiple languages, including Chinese, English, Mandarin, Cantonese, and English [1] - The model enhances general medical diagnosis capabilities and enables in-depth specialized diagnostic reasoning [1]